GLP-1 Receptor Agonists (GLP-1RAs)

Experienced acute pancreatitis while taking GLP-1 medicines like Ozempic or Mounjaro?

Join the Yellow Card Biobank study to help researchers understand whether your genes cause side effects from medicines and make treatments safer for all.

About the study The Yellow Card Biobank is a collaboration between the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England.

It’s a pilot study to better understand whether a person’s genetic make-up may make them more likely to experience a severe side effect from certain medicines. By learning more, the study aims to make medicines safer for everyone, but we need those who experience adverse reactions to report a Yellow Card.

Report a severe reaction to a GLP-1 RA used to treat type 2 diabetes or for weight loss

Right now, we want to hear from people who have or are taking the drug Glucagon-like peptide-1 receptor agonists (GLP-1s or GLP-1 RAs) to treat type 2 diabetes or for weight loss. You may know these drugs by their brand names, such as Wegovy, Ozempic, Saxenda, Rybelsus and Mounjaro. We are recruiting people who have experienced and been diagnosed with acute pancreatitis, a known side effect of the drug.

This includes individuals who have been prescribed this medicine by their doctor or another healthcare professional and anyone who has bought it online.

What are GLP-1s?

GLP-1 agonists are a class of medicines that work like a natural hormone in your body, GLP-1 hormone, to help manage type 2 diabetes. Some of these medicines are also used to support weight loss.

In the United Kingdom, there are three licensed GLP-1 medicines:

• Semaglutide (sold as Wegovy and Ozempic)

• Tirzepatide (sold as Mounjaro)

• Liraglutide (sold as Victoza and Saxenda)

These medicines have become better known recently because of their use in weight loss/management. However, it's important to know that not all GLP-1 medicines are licensed for this purpose.